Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asundexian for prevention of ischemic stroke after acute non-cardioembolic stroke or high-risk TIA
NCT05686070Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Asundexian with Placebo (2 arms). Primary endpoints: Time to first occurrence of ischemic stroke at 31 months and Time to first occurrence of ISTH major bleeding at 31 months. Started Jan 2023; status: completed.
02
Drugs
asundexian
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05686070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686070.